Literature DB >> 22003003

Personalized vascular medicine: individualizing drug therapy.

Emil M Degoma1, Giovanni Rivera, Scott M Lilly, M Haris U Usman, Emile R Mohler.   

Abstract

Personalized medicine refers to the application of an individual's biological fingerprint - the comprehensive dataset of unique biological information - to optimize medical care. While the principle itself is straightforward, its implementation remains challenging. Advances in pharmacogenomics as well as functional assays of vascular biology now permit improved characterization of an individual's response to medical therapy for vascular disease. This review describes novel strategies designed to permit tailoring of four major pharmacotherapeutic drug classes within vascular medicine: antiplatelet therapy, antihypertensive therapy, lipid-lowering therapy, and antithrombotic therapy. Translation to routine clinical practice awaits the results of ongoing randomized clinical trials comparing personalized approaches with standard of care management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22003003      PMCID: PMC3761360          DOI: 10.1177/1358863X11422251

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  111 in total

1.  Laragh's lessons in pathophysiology and clinical pearls for treating hypertension.

Authors:  J Laragh
Journal:  Am J Hypertens       Date:  2001-04       Impact factor: 2.689

2.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

3.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Philip Greenland; Joseph S Alpert; George A Beller; Emelia J Benjamin; Matthew J Budoff; Zahi A Fayad; Elyse Foster; Mark A Hlatky; John McB Hodgson; Frederick G Kushner; Michael S Lauer; Leslee J Shaw; Sidney C Smith; Allen J Taylor; William S Weintraub; Nanette K Wenger; Alice K Jacobs
Journal:  Circulation       Date:  2010-11-15       Impact factor: 29.690

Review 4.  The prospects for "personalized medicine" in drug development and drug therapy.

Authors:  J Woodcock
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

5.  The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.

Authors:  K A Kim; P W Park; S J Hong; J-Y Park
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

6.  Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

Authors:  Chee Tang Chin; Matthew T Roe; Keith A A Fox; Dorairaj Prabhakaran; Debra A Marshall; Helene Petitjean; Yuliya Lokhnygina; Eileen Brown; Paul W Armstrong; Harvey D White; E Magnus Ohman
Journal:  Am Heart J       Date:  2010-07       Impact factor: 4.749

7.  Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

Authors:  Charles J Glueck; Dawit Aregawi; Mahlia Agloria; Qasim Khalil; Magdalena Winiarska; Jitender Munjal; Srikanth Gogineni; Ping Wang
Journal:  Clin Ther       Date:  2006-06       Impact factor: 3.393

Review 8.  Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.

Authors:  Jasper J Brugts; Eric Boersma; Maarten L Simoons
Journal:  Pharmacogenomics       Date:  2010-08       Impact factor: 2.533

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.

Authors:  David A Flockhart; Dennis O'Kane; Marc S Williams; Michael S Watson; David A Flockhart; Brian Gage; Roy Gandolfi; Richard King; Elaine Lyon; Robert Nussbaum; Dennis O'Kane; Kevin Schulman; David Veenstra; Marc S Williams; Michael S Watson
Journal:  Genet Med       Date:  2008-02       Impact factor: 8.822

View more
  6 in total

Review 1.  Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.

Authors:  Andrzej S Krolewski; Tomohito Gohda; Monika A Niewczas
Journal:  Clin Exp Nephrol       Date:  2013-11-12       Impact factor: 2.801

2.  High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline.

Authors:  Andrzej S Krolewski; Joseph V Bonventre
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

3.  The Association between Gly460Trp-Polymorphism of Alpha-Adducin 1 Gene (ADD1) and Arterial Hypertension Development in Ukrainian Population.

Authors:  Svitlana Yermolenko; Yaroslav Chumachenko; Viktor Orlovskyi; Irina Moiseyenko; Oleksandr Orlovskyi
Journal:  Int J Hypertens       Date:  2021-05-04       Impact factor: 2.420

4.  Prediction of Ischemic Events after Percutaneous Coronary Intervention: Thrombelastography Profiles and Factor XIIIa Activity.

Authors:  Rolf P Kreutz; Glen Schmeisser; Andrea Schaffter; Sri Kanuri; Janelle Owens; Benjamin Maatman; Anjan Sinha; Elisabeth von der Lohe; Jeffrey A Breall
Journal:  TH Open       Date:  2018-04

5.  Quantile-dependent expressivity of postprandial lipemia.

Authors:  Paul T Williams
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

6.  Personalized medicine in cardiovascular diseases.

Authors:  Moo-Sik Lee; Andreas J Flammer; Lilach O Lerman; Amir Lerman
Journal:  Korean Circ J       Date:  2012-09-27       Impact factor: 3.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.